In this role, Camille will oversee all medical and scientific communication between community members and pharmaceutical industry/healthcare partners.
Birmingham, AL ( April 18, 2022) - Acclinate, a leading digital health company, announced the appointment of Camille Pope, PharmD as Chief Medical Lead. She brings 14+ years of pharmaceutical industry experience to the company. In this role, Camille will oversee all medical and scientific communication between community members and pharmaceutical industry/healthcare partners. She will also contribute strategic market intelligence to help further develop Acclinate’s platform and services.
“Acclinate has made great strides in building a world-class team and developing innovative technologies to drive sustained community engagement leading to greater clinical trial diversity," said Dr. Pope. "I'm thrilled to join the Acclinate team and work with such a talented group of individuals on our quest to achieve health equity through inclusive research".
With experience in medical affairs across several therapeutic areas, Camille is a proven pharmaceutical industry leader with extensive drug launch experience. Before joining Acclinate, Camille served as the US Medical Lead for Prostate Cancer at AstraZeneca and as a Senior MedicalScience Liaison for Hepatitis C & HIV at Abbvie. She was recognized for her leadership by AstraZeneca's Rising Leaders Program and the She-Suite BrandLeadership Institute.
"Camille is a key leadership addition to our team," said Del Smith, CEO and co-founder of Acclinate. "Her extensive domain knowledge and demonstrated passion for health equity will be a tremendous asset as we continue to scale."
As an experienced healthcare professional with demonstrated expertise in diversity and inclusion, Camille is enthusiastic about fostering diverse talent and striving for health equity. She has championed several projects to address clinical trial diversity gaps and established AstraZeneca's US Medical Oncology Inclusion& Diversity Talent Recruitment Workstream, which led to new partnerships with Howard University’s College of Pharmacy and the Tom Joyner Foundation.
"Acclinate continues to break down barriers for communities of color in the clinical trial space and create a more robust and efficient process for researchers and sponsors," said CDO and co-founder Tiffany Whitlow. "Leading the charge in diversifying clinical trials requires a top-tier team that exhibits leadership. I look forward to working with Camille to implement innovative strategies that will help us scale and enhance our offering.
Camille holds a Doctor of Pharmacy degree from Florida Agricultural and Mechanical University. She completed a Post-DoctoralMedical Strategy Fellowship with Bristol-Myers Squibb/Rutgers Institute for Pharmaceutical Industry Fellowships. Camille is currently earning her graduate certificate in Health Disparities Research from University of Illinois Chicago.
Acclinate™ is a Birmingham-based digital health company helping pharmaceutical companies and healthcare organizations access and engage communities of color so that research is more inclusive.